Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The aim of this RCT is to compare differences in the efficacy and safety between cleavage-stage embryo transfer and blastocyst-stage embryo transfer in IVF/ICSI treatment cycle, taking into account of subsequent vitrified embryo transfers. Subjects with 3 or more transferrable cleavage embryos will be randomized to the cleavage-stage or blastocyst-stage embryos transfer group. The primary outcome is cumulative live birth rate (CLBR) per patient until the first live birth from one initiated oocyte retrieval cycle, calculated using outcomes from the first three embryo transfers within 1 year after randomization.
Description: Cumulative live birth rate (CLBR) is defined the first live birth per patient from one initiated oocyte retrieval cycle(Calculated using outcomes from the first three embryo transfers within 1 year after randomization). Live birth is defined as delivery of any neonate ≥24 weeks gestation with heart beat and breath.
Measure: cumulative live birth rate Time: 30 monthsDescription: Biochemical pregnancy is defined as a serum β-HCG level of at least 25 IU/L 14 days after embryo transfer.
Measure: biochemical pregnancy rate Time: 30 monthsDescription: Clinical pregnancy is defined by the presence of intrauterine gestation sacs at 30-35 days after embryo transfer.
Measure: clinical pregnancy rate Time: 30 monthsDescription: Ongoing pregnancy is defined as a viable pregnancy at 12 weeks gestation.
Measure: ongoing pregnancy rate Time: 30 monthsDescription: Pregnancy loss is defined as a pregnancy that results in a spontaneous abortion or therapeutic abortion that occurred throughout pregnancy.
Measure: Pregnancy loss rate Time: 30 monthsDescription: Number of patients with moderate or severe OHSS/ number of COS cycles.
Measure: moderate or severe OHSS rate Time: 12 monthsDescription: diagnosed by ultrasound examination or laparoscopic surgery visualizing more than or equal to 1 gestational sacs outside the uterus or by abnormally increasing serum hCG level without sonographic visualization and the absence of chorionic villi inside the uterus after uterine curettage, which was treated by methotrexate.
Measure: ectopic pregnancy Time: 24 monthsDescription: the ratio of males to females in the newborns
Measure: sex ratio Time: 30 monthsDescription: Number of multiple pregnancies / number of clinical pregnancies.
Measure: multiple pregnancy Time: 30 monthsDescription: Number of pregnancies with complications / number of pregnancies; ;number of live births with neonatal complications / number of live births
Measure: incidence of obstetric and perinatal complications Time: 30 monthsDescription: structural or functional anomalies that occur during intrauterine life and can be identified prenatally, at birth or later in life.
Measure: congenital anomalies Time: 30 monthsDescription: the number of gestational sacs detected with sonography at 6 weeks of pregnancy/the number of embryos transferred
Measure: implantation rate Time: 30 monthsDescription: Weight of newborns at delivery
Measure: Birth weight Time: 30 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports